We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Hematology Diagnostics Market to Reach USD 5.6 Billion by 2026

By LabMedica International staff writers
Posted on 22 Aug 2019
The global hematology diagnostics market is projected to grow at a CAGR of 5.0% from USD 3.50 billion in 2017 to USD 5.59 billion by 2026, driven by the growing occurrence of blood disorders and increased adoption of automated testing processes.

These are the latest findings of Transparency Market Research, (Albany, NY, USA), a global market intelligence company providing business information reports and services.

The WHO has declared that hemoglobin disorders are now substantially common among 89% of the births in 71% of countries. More...
Nearly 1.1% of couples across the globe are at risk of giving birth to children with a hemoglobin disorder and around 2.7 of every 1,000 conceptions are affected by hemoglobin. Additionally, the WHO states that least 20% of the global population is a carrier of α+ thalassaemia. This high prevalence of hemoglobin disorders is fueling the growth of the global hematology diagnostics market.

Additionally, the growth of global hematology diagnostics market is being further driven by automation, which is the main focal point for hematology labs. The automation of hematology diagnostics processes has resulted in reduced turnaround time, which has sped up the treatment regimen for blood disorders in general. Several laboratories across the world are adopting automation for pre-analytical, analytical, and post analytical processes to standardize and improve the process.

Geographically, the global hematology diagnostics market is expected to be dominated by North America due to the growing prevalence of various types of blood diseases and presence of prominent market players in the region. Europe is the world’s second-largest hematology diagnostics market due to the growing importance of hematology research in the region. Additionally, Asia-Pacific is estimated to be one of the fastest growing regions in the global hematology diagnostics market due to the growing prevalence of genetic diseases and blood disorders in the region.

Related Links:
Transparency Market Research


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.